Screener
Ultragenyx Pharmaceutical RARE Cash Flow Statement
| Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | ||
|---|---|---|---|---|---|---|
| -$92M+20.0% | -$185M-22.5% | -$128.56M+3.5% | -$180.41M-35.1% | -$115M+12.6% | ||
| $8M-11.1% | $8M-11.1% | $8.79M-7.9% | $8.22M-6.2% | $9M+1.6% | ||
| -$97M+11.0% | -$197M-18.7% | -$99.83M-25.9% | -$91.17M-36.1% | -$109M-41.6% | ||
| $1M-66.7% | $1M0.0% | $938K+475% | $1.06M-34.3% | $3M+49.3% | ||
| —— | -$49M-141% | —— | $117.25M+143% | $71M+17.2% | ||
| —— | —— | $394.19M+13,285% | $0-100% | $83.84M-78.2% | ||
| -$49M-198% | -$247M-449% | $221.46M— | $25.54M+108% | $50M-86.4% | ||
| -$98M+12.5% | -$198M-18.6% | -$100.77M-26.8% | -$92.23M-34.4% | -$112M-41.8% |
FAQ
- How much cash does Ultragenyx Pharmaceutical generate?
- Ultragenyx Pharmaceutical (RARE) generated -$485.0M in operating cash flow over the trailing twelve months.
- What is Ultragenyx Pharmaceutical's free cash flow?
- After $4.0M of capital expenditures, Ultragenyx Pharmaceutical's free cash flow was -$489.0M over the trailing twelve months, down 14.5% year over year.
- Where does Ultragenyx Pharmaceutical's cash flow data come from?
- Every line is extracted from Ultragenyx Pharmaceutical's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
